vs
GENMAB A/S（GMAB）与Take-Two Interactive（TTWO）财务数据对比。点击上方公司名可切换其他公司
Take-Two Interactive的季度营收约是GENMAB A/S的1.8倍（$1.7B vs $925.0M），GENMAB A/S净利率更高（36.3% vs -5.5%，领先41.8%），Take-Two Interactive同比增速更快（24.9% vs 18.7%），GENMAB A/S自由现金流更多（$327.0M vs $236.2M）
Genmab A/S是丹麦生物技术企业，1999年2月由原BankInvest生物医药风险基金董事总经理Florian Schönharting创立，总部位于丹麦哥本哈根，在荷兰乌得勒支、美国新泽西州普林斯顿、日本东京、德国慕尼黑及中国苏州均设有子公司，深耕生物科技领域的研发与运营。
Take-Two Interactive是总部位于美国纽约的电子游戏控股企业，由瑞安·布兰特于1993年9月创立，在全球互动娱乐领域拥有较高影响力，业务覆盖游戏研发、发行与运营等核心环节。
GMAB vs TTWO — 直观对比
营收规模更大
TTWO
是对方的1.8倍
$925.0M
营收增速更快
TTWO
高出6.2%
18.7%
净利率更高
GMAB
高出41.8%
-5.5%
自由现金流更多
GMAB
多$90.8M
$236.2M
损益表 — Q2 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $925.0M | $1.7B |
| 净利润 | $336.0M | $-92.9M |
| 毛利率 | 93.8% | 55.7% |
| 营业利润率 | 38.9% | -2.3% |
| 净利率 | 36.3% | -5.5% |
| 营收同比 | 18.7% | 24.9% |
| 净利润同比 | 65.5% | 25.8% |
| 每股收益（稀释后） | $5.42 | $-0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMABTTWO
| Q4 25 | — | $1.7B | ||
| Q3 25 | — | $1.8B | ||
| Q2 25 | $925.0M | $1.5B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | $779.0M | $1.3B | ||
| Q1 24 | — | $1.4B |
净利润GMABTTWO
| Q4 25 | — | $-92.9M | ||
| Q3 25 | — | $-133.9M | ||
| Q2 25 | $336.0M | $-11.9M | ||
| Q1 25 | — | $-3.7B | ||
| Q4 24 | — | $-125.2M | ||
| Q3 24 | — | $-365.5M | ||
| Q2 24 | $203.0M | $-262.0M | ||
| Q1 24 | — | $-2.9B |
毛利率GMABTTWO
| Q4 25 | — | 55.7% | ||
| Q3 25 | — | 55.3% | ||
| Q2 25 | 93.8% | 62.8% | ||
| Q1 25 | — | 50.8% | ||
| Q4 24 | — | 55.9% | ||
| Q3 24 | — | 53.8% | ||
| Q2 24 | 96.4% | 57.6% | ||
| Q1 24 | — | 33.5% |
营业利润率GMABTTWO
| Q4 25 | — | -2.3% | ||
| Q3 25 | — | -5.5% | ||
| Q2 25 | 38.9% | 1.4% | ||
| Q1 25 | — | -238.7% | ||
| Q4 24 | — | -9.7% | ||
| Q3 24 | — | -22.0% | ||
| Q2 24 | 30.3% | -13.8% | ||
| Q1 24 | — | -193.9% |
净利率GMABTTWO
| Q4 25 | — | -5.5% | ||
| Q3 25 | — | -7.5% | ||
| Q2 25 | 36.3% | -0.8% | ||
| Q1 25 | — | -235.5% | ||
| Q4 24 | — | -9.2% | ||
| Q3 24 | — | -27.0% | ||
| Q2 24 | 26.1% | -19.6% | ||
| Q1 24 | — | -207.4% |
每股收益（稀释后）GMABTTWO
| Q4 25 | — | $-0.50 | ||
| Q3 25 | — | $-0.73 | ||
| Q2 25 | $5.42 | $-0.07 | ||
| Q1 25 | — | $-21.27 | ||
| Q4 24 | — | $-0.71 | ||
| Q3 24 | — | $-2.08 | ||
| Q2 24 | $3.13 | $-1.52 | ||
| Q1 24 | — | $-17.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $2.4B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $5.3B | $3.5B |
| 总资产 | $6.5B | $10.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GMABTTWO
| Q4 25 | — | $2.4B | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | $1.3B | $2.0B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $879.6M | ||
| Q2 24 | $622.0M | $1.1B | ||
| Q1 24 | — | $776.0M |
股东权益GMABTTWO
| Q4 25 | — | $3.5B | ||
| Q3 25 | — | $3.4B | ||
| Q2 25 | $5.3B | $3.5B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $5.7B | ||
| Q3 24 | — | $5.8B | ||
| Q2 24 | $4.4B | $6.0B | ||
| Q1 24 | — | $5.7B |
总资产GMABTTWO
| Q4 25 | — | $10.0B | ||
| Q3 25 | — | $10.1B | ||
| Q2 25 | $6.5B | $9.7B | ||
| Q1 25 | — | $9.2B | ||
| Q4 24 | — | $12.7B | ||
| Q3 24 | — | $13.1B | ||
| Q2 24 | $5.6B | $12.9B | ||
| Q1 24 | — | $12.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $349.0M | $305.2M |
| 自由现金流经营现金流 - 资本支出 | $327.0M | $236.2M |
| 自由现金流率自由现金流/营收 | 35.4% | 13.9% |
| 资本支出强度资本支出/营收 | 2.4% | 4.1% |
| 现金转化率经营现金流/净利润 | 1.04× | — |
| 过去12个月自由现金流最近4个季度 | — | $487.8M |
8季度趋势，按日历期对齐
经营现金流GMABTTWO
| Q4 25 | — | $305.2M | ||
| Q3 25 | — | $128.4M | ||
| Q2 25 | $349.0M | $-44.7M | ||
| Q1 25 | — | $279.0M | ||
| Q4 24 | — | $-4.8M | ||
| Q3 24 | — | $-128.4M | ||
| Q2 24 | $438.0M | $-191.0M | ||
| Q1 24 | — | $-8.9M |
自由现金流GMABTTWO
| Q4 25 | — | $236.2M | ||
| Q3 25 | — | $96.5M | ||
| Q2 25 | $327.0M | $-69.8M | ||
| Q1 25 | — | $224.9M | ||
| Q4 24 | — | $-48.2M | ||
| Q3 24 | — | $-165.2M | ||
| Q2 24 | $430.0M | $-226.1M | ||
| Q1 24 | — | $-55.1M |
自由现金流率GMABTTWO
| Q4 25 | — | 13.9% | ||
| Q3 25 | — | 5.4% | ||
| Q2 25 | 35.4% | -4.6% | ||
| Q1 25 | — | 14.2% | ||
| Q4 24 | — | -3.5% | ||
| Q3 24 | — | -12.2% | ||
| Q2 24 | 55.2% | -16.9% | ||
| Q1 24 | — | -3.9% |
资本支出强度GMABTTWO
| Q4 25 | — | 4.1% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | 2.4% | 1.7% | ||
| Q1 25 | — | 3.4% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | 1.0% | 2.6% | ||
| Q1 24 | — | 3.3% |
现金转化率GMABTTWO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.04× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.16× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GMAB
| Darzalex | $638.0M | 69% |
| Kesimpta | $108.0M | 12% |
| Net Product Sales | $101.0M | 11% |
| Other | $28.0M | 3% |
| Tepezza | $20.0M | 2% |
| Reimbursement Revenue | $13.0M | 1% |
| Bio N Tech | $11.0M | 1% |
| Abb Vie | $5.0M | 1% |
| Milestone Revenue | $1.0M | 0% |
TTWO
暂无分部数据
